Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Roth Capital Downgrades Apellis Pharmaceuticals to Neutral, Lowers Price Target to $40

Roth Capital analyst Elemer Piros downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Buy to Neutral and lowers the price target from $46 to $40.
byBenzinga Newsdesk
November 29, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Roth Capital analyst Elemer Piros downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Buy to Neutral and lowers the price target from $46 to $40.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts